Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa Mar 8, 2017
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference Mar 7, 2017
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai Mar 3, 2017
Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress Feb 21, 2017
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017 Feb 17, 2017
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017 Feb 7, 2017
Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A Feb 1, 2017
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B Jan 19, 2017
